Trump Administration Imposes Temporary Import Duties Following Supreme Court Ruling
Despite recent legal challenges to the Trump administration’s sweeping tariffs, a Section 232 investigation is ongoing for imports of medical...
1 min read
On May 29, Medicare announced it would expand coverage for genomic sequence analysis panels in the treatment of hematolymphoid diseases.
The local coverage determination (LCD) “provides limited coverage for genomic sequence analysis panels under specific clinical circumstances.” Specifically, these multi-gene panel tests would be used for diagnosis, risk stratification, and treatment planning for patients with hematolymphoid diseases, including newly diagnosed or relapsed/refractory acute myelogenous leukemia, myelodysplastic syndromes with nondiagnostic assessments, and myeloproliferative neoplasms requiring risk stratification or disease monitoring.
The College of American Pathologists applauded the proposed updates in a 2024 letter, expressing support for the decision to broaden coverage. According to CAP, the policy aligns with the National Comprehensive Cancer Network guidelines and the World Health Organization classifications.
The revision is effective for services performed on or after July 13, 2025.
Sources:
https://www.cap.org/advocacy/latest-news-and-practice-data/june-10-2025#story5
UHC Routine Testing Management Policies to Be Implemented in Three More States in April
UnitedHealthcare (UHC) is now implementing new Routine Testing Management Policies for laboratory services, tests, and procedures in North Carolina,...
TELCOR Sponsors Sonic Medical Leadership Summit 2026
Lincoln, Nebraska – February 24, 2026 – TELCOR Inc is proud to be an Ultimate Diamond Partner of the Sonic Healthcare USA Medical Leadership Summit, ...